Semaglutide

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes by enhancing insulin secretion, reducing appetite, and promoting weight loss. It is administered as a subcutaneous injection once weekly and has shown significant efficacy in improving glycemic control and reducing body weight.

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar through glucagon suppression.

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15-19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes.

17 Sep 2025

GLP-1 drugs found to protect against diabetic retinopathy

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published in the journal Pharmaceutics.

17 Sep 2025

Higher-dose semaglutide helps people lose nearly 19% of body weight

The STEP UP trial reveals semaglutide 7.2 mg significantly reduces weight compared to 2.4 mg, though it raises questions about gastrointestinal side effects.

16 Sep 2025

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live longer and face fewer serious health problems compared with those treated with GLP-1 receptor agonist medicines alone.

16 Sep 2025

Individuals taking semaglutide for weight loss experience less food noise than before

New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) shows that individuals who are taking semaglutide for weight loss experience less food noise than before.

16 Sep 2025

GLP-1 drugs may offer cost-effective treatment for people with knee osteoarthritis and obesity

A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee osteoarthritis and obesity, with tirzepatide providing greater health benefits at lower cost compared to semaglutide.

16 Sep 2025

Study: Half of adults without diabetes taking weight-loss drug discontinue treatment within a year

The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals lose weight.

15 Sep 2025

Are GLP-1 drugs safe for women planning pregnancy?

A study reveals rising GLP-1 prescriptions in young women, highlighting low contraception use and potential risks for unintended pregnancies and fetal outcomes.

12 Sep 2025

Scientists uncover brain circuit that turns cravings into eating behavior

Researchers found that the bed nucleus of the stria terminalis integrates pleasure signals from central amygdala prodynorphin neurons and hunger signals from agouti-related peptide neurons to drive consumption. Manipulating this bed nucleus of the stria terminalis circuit bidirectionally altered food intake and body weight in mice.

11 Sep 2025

Study challenges conventional thinking about the onset of Type 2 diabetes

A study from The University of Texas at San Antonio Health Science Center indicates that changes in the body that lead to Type 2 diabetes occur long before current diagnostic thresholds for prediabetes are met.

11 Sep 2025

WHO expands essential medicines lists with new cancer and diabetes treatments

Today, the World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.

5 Sep 2025

Semaglutide may one day be used to treat cocaine addiction

A drug already prescribed for type 2 diabetes and obesity may one day be used to treat cocaine addiction. In animal studies, researchers at the University of Gothenburg, Sweden, found that semaglutide reduced both cocaine use and relapse.

5 Sep 2025

Weight loss medication semaglutide reduces cocaine seeking behavior in animal study

Scientists have found that the diabetes/weight loss drug Semaglutide, sold commercially under brand names like Ozempic and Wegovy, significantly reduces cocaine-seeking behaviour in rats.

4 Sep 2025

$New hypothesis links internal fat biology to heart failure with preserved ejection fraction$

New hypothesis links internal fat biology to heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction (HFpEF) appears to develop as a result of changes in the biology of a person's internal fat tissue, according to the Adipokine Hypothesis, a new way of understanding how fat may impact the heart.

1 Sep 2025

Increasing numbers of bariatric surgery patients turn to GLP-1 drugs

Bariatric surgery is usually effective on its own for weight loss, but an increasing proportion of patients who undergo bariatric surgery start taking one of the new glucagon-like 1 peptide receptor agonist (GLP-1) weight-loss drugs in the years after their surgery, according to a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health.

27 Aug 2025

GLP-1 receptor agonists improve heart failure outcomes and reduce environmental impact

New research has found that the use of GLP-1 receptor agonists, a class of medications commonly prescribed for patients with obesity and diabetes, reduces the environmental footprint of healthcare and clinical outcomes when used to treat heart failure.

27 Aug 2025

Do GLP-1 drugs shrink your muscles? New study explains the risks and what to do

GLP-1 receptor agonists are transforming obesity and diabetes care, but may reduce skeletal muscle mass, raising concerns about sarcopenic obesity. This comprehensive review explores the mechanisms, clinical implications, and mitigation strategies, including exercise, protein intake, and adjunct therapies.

26 Aug 2025

Study clarifies how amylin receptors respond to drugs

Amylin, a hormone that controls appetite and blood sugar by activating three different receptors in the brain, could be the basis for the next blockbuster obesity drugs.

19 Aug 2025

Scientists urge shift in medicine to target the biology of aging

The most recent issue of Journal of the American Medical Association includes a landmark review highlighting innovative strategies to slow the biological aging process, an emerging approach with significant potential to prevent or delay multiple chronic diseases at once, one of the most pressing challenges in modern medicine today.

18 Aug 2025

GIPR signaling opens brain’s gate for GLP-1 weight-loss therapy

A Cell Metabolism study reveals that GIPR signaling in oligodendrocytes enhances brain access and weight-loss efficacy of GLP-1R agonists by increasing vascular permeability and targeting appetite-regulating neurons. This mechanism may explain why GIPR/GLP-1R co-agonists outperform single-agent therapies.

14 Aug 2025